BC
CPRX

Bridgefront Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Bridgefront Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,398
Closed -$555K – 556
2026
Q1 		$555K Buy
+22,398
New +$534K 0.14% 250
2023
Q2 		– Sell
-10,340
Closed -$171K – 492
2023
Q1 		$171K Sell
10,340
-6,931
-40% -$114K 0.1% 362
2022
Q4 		$321K Buy
+17,271
New +$266K 0.22% 192
2021
Q3 		– Sell
-27,460
Closed -$158K – 401
2021
Q2 		$158K Buy
27,460
+6,834
+33% +$35.3K 0.06% 527
2021
Q1 		$95K Buy
+20,626
New +$81.9K 0.03% 625

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bridgefront Capital's CPRX Position: Q2 2026 in Review

Bridgefront Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 22,398 shares — an estimated $555K sold.

Bridgefront Capital first reported a position in CPRX in Q1 2021 and held it in 5 quarters. The position peaked at $555K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Bridgefront Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 22,398 Catalyst Pharmaceutical shares in Q2 2026, an estimated $555K.
  • Bridgefront Capital first reported a position in Catalyst Pharmaceutical in Q1 2021 and held it in 5 quarters.
  • Bridgefront Capital's Catalyst Pharmaceutical position peaked at $555K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.